Source link : https://www.newshealth.biz/health-news/car-t-benefits-both-young-and-old/
Older adults with relapsed/refractory large B-cell lymphoma (R/R LBCL) treated with CD19-directed chimeric antigen receptor (CAR) T-cell therapy show no significant differences in key survival outcomes vs younger patients, suggesting important benefits for the age group of patients that commonly are diagnosed with this subtype of non-Hodgkin lymphoma. “This real-world study demonstrates that CD19 CAR-T […]
Author : News Health
Publish date : 2024-07-30 06:15:55
Copyright for syndicated content belongs to the linked Source.